A country guide to clinical trials in Spain; AEMPS approvals, oncology leadership, Barcelona and Madrid research hubs, patient recruitment, and one of Europe's strongest site ecosystems.
Spain is Southern Europe's largest country by area and one of its most populous, with 47 million people spread across a highly regionalized territory. It is a founding EU member and one of the bloc's most economically significant states, with a GDP of approximately €1.4 trillion. Its healthcare system; the National Health System (SNS); is universally funded and consistently ranked among the best in the world for outcomes and coverage. Geographically, Spain bridges Northern Europe and North Africa, giving it access to a uniquely diverse patient demographic. Madrid and Barcelona are the twin poles of the country's clinical research ecosystem, though major regional centers in Valencia, Seville, Bilbao, and Salamanca add substantial depth.
Spain's pharmaceutical industry invested €849 million in clinical trials alone between 2012 and 2022, with R&D investment growing 74% over that decade to reach €1.4 billion. Spain is also the first EU member state to have fully implemented the EU Clinical Trials Regulation (CTR 536/2014), doing so years before most peers; a head start that has directly contributed to its regulatory speed advantage and European leadership position.
Spain's 47 million people represent one of Europe's most ethnically and culturally diverse populations, reflecting centuries of Mediterranean influence and decades of immigration from Latin America, North Africa, Eastern Europe, and Sub-Saharan Africa. This makes Spain particularly valuable for trials requiring demographic breadth; not just scale. The population skews older (median age ~44), driving strong demand for research in oncology, cardiology, neurology, and rheumatology. Urban concentration in Madrid (~3.3M), Barcelona (~1.6M), and Valencia (~800K) creates dense, accessible patient pools for high-volume enrollment.
Scale in context: Spain participates in 1 in every 3 clinical trials launched in Europe, and in 2021 ranked second globally; behind only the United States; in participation in clinical trials of new drugs. More than 145,000 patients participated in clinical studies in 2023.
Spain's dominance in European clinical research is structural, not accidental. It was built over two decades through early regulatory harmonization, investment in research infrastructure, and a culture of public-private collaboration through Farmaindustria's BEST Project. In 2024 AEMPS authorized 930 clinical studies; the highest in the EU, ahead of France and Germany; and coordinated 770 multinational studies, serving as Reference Member State in 28% of them.
Spain was the first EU country to implement the EU CTR. Clinical trials can be activated in approximately 3 months from the start of the process. AEMPS introduced a fast-track evaluation procedure in 2024.
Lower operational costs than Germany, France, or the UK. Strong public healthcare infrastructure means lower site overhead. Spain delivers Western European quality at a competitive price point.
47 million people; 145,000+ trial participants in 2023. A culture of volunteer participation, universal healthcare coverage, and a diverse genetic and ethnic makeup spanning European, Latin, North African, and Middle Eastern heritage.
35 accredited Health Research Institutes (ISCIII), over 31,000 researchers, 5,368 active trials in Catalonia alone. Barcelona ranks among the world's top cities for clinical trial volume. Vall d'Hebron alone manages 1,580+ active trials.
Oncology is Spain's dominant research area; 336 cancer drug trials were authorized in 2024, representing 37.6% of all studies, and Spain leads the EU in advanced therapy trials (52 authorized in 2024). The country is also a European leader in research with biotech medicines, rare diseases (22% of all studies), and immunology. VHIO in Barcelona is one of the continent's most active Phase I oncology sites. Neurology and immune system disorders round out the top three therapeutic categories.
Spain's research activity concentrates in Barcelona and Madrid, which together account for the vast majority of trial volume. Barcelona's hospital campus ecosystem; Vall d'Hebron, Hospital Clínic, Hospital Sant Pau; gives the city a density of research excellence unmatched by any comparably sized European city outside London or Paris.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Vall d'Hebron University Hospital / VHIO | Barcelona | Spain's most active trial site; 1,580+ active trials; VHIO is a top-5 European Phase I oncology center with Molecular Prescreening Program; VHIR manages research; campus also hosts Cemcat (MS) and UAB. |
| 02 | Hospital Clínic de Barcelona (FCRB-IDIBAPS) | Barcelona | National and European reference center for advanced therapies; promotes the most clinical studies in Catalonia; strong in oncology, hepatology, cardiology, and immunology. |
| 03 | Hospital General Universitario Gregorio Marañón | Madrid | 637 active Phase I–III trials; 250 in oncology; one of Spain's two or three largest trial-volume hospitals; leading in cardiology, infectious disease, and pediatrics. |
| 04 | Hospital Universitario La Paz | Madrid | 424 new studies initiated in 2024; Spain's only hospital with all pediatric specialties; driving exceptional pediatric research output; IdiPAZ research institute on campus. |
| 05 | Hospital Universitario 12 de Octubre | Madrid | Major oncology and hematology research hub; strong CAR-T and advanced therapy program; university hospital with broad Phase II–IV portfolio. |
| 06 | Hospital de la Santa Creu i Sant Pau | Barcelona | IIB Sant Pau research institute; UNESCO World Heritage site and major academic research center; active in oncology, neurology, and cardiovascular trials. |
| 07 | Hospital Universitario Ramón y Cajal | Madrid | Reference center for oncology, hematology, and rheumatology; IRYCIS research institute; significant Phase II–IV trial portfolio. |
| 08 | Hospital Universitari de Bellvitge | Barcelona | IDIBELL research institute; oncology, hematology, and transplantation specialist; one of Catalonia's most active trial sites. |
| 09 | Clínica Universidad de Navarra | Pamplona / Madrid | Private academic hospital; internationally recognized for oncology and personalized medicine; pioneered CAR-T in Spain; campuses in Pamplona and Madrid. |
| 10 | Hospital Universitario Virgen del Rocío | Seville | Southern Spain's largest hospital (1,521 beds); major oncology, rare disease, and gene therapy trial activity; IBiS research institute. |
| 11 | MD Anderson Cancer Center Madrid | Madrid | Spanish affiliate of MD Anderson; dedicated oncology trials site; Phase I–III; strong in solid tumors and hematologic malignancies. |
| 12 | Hospital del Mar (IMIM) | Barcelona | IMIM research institute; strong in cardiovascular, neuroscience, oncology, and infectious disease trials; active Phase I program. |
| 13 | Hospital Universitario de Salamanca | Salamanca | Spain's leading hematology center; nationally recognized for multiple myeloma, lymphoma, and hematopoietic cell transplantation trials. |
| 14 | Hospital Germans Trias i Pujol (Can Ruti) | Badalona | IGTP research institute; strong in infectious disease (HIV), oncology, and immunology; major Phase II–IV site in the Barcelona metropolitan area. |
| 15 | NEXT Oncology (Quirónsalud network) | Madrid / Barcelona | Dedicated Phase I oncology centers within the Quirónsalud Group; early-phase first-in-human and first-in-class oncology trials across both campuses. |
Spain's most active trial site; 1,580+ active trials; VHIO is a top-5 European Phase I oncology center with Molecular Prescreening Program; VHIR manages research; campus also hosts Cemcat (MS) and UAB.
National and European reference center for advanced therapies; promotes the most clinical studies in Catalonia; strong in oncology, hepatology, cardiology, and immunology.
637 active Phase I–III trials; 250 in oncology; one of Spain's two or three largest trial-volume hospitals; leading in cardiology, infectious disease, and pediatrics.
424 new studies initiated in 2024; Spain's only hospital with all pediatric specialties; driving exceptional pediatric research output; IdiPAZ research institute on campus.
Major oncology and hematology research hub; strong CAR-T and advanced therapy program; university hospital with broad Phase II–IV portfolio.
IIB Sant Pau research institute; UNESCO World Heritage site and major academic research center; active in oncology, neurology, and cardiovascular trials.
Reference center for oncology, hematology, and rheumatology; IRYCIS research institute; significant Phase II–IV trial portfolio.
IDIBELL research institute; oncology, hematology, and transplantation specialist; one of Catalonia's most active trial sites.
Private academic hospital; internationally recognized for oncology and personalized medicine; pioneered CAR-T in Spain; campuses in Pamplona and Madrid.
Southern Spain's largest hospital (1,521 beds); major oncology, rare disease, and gene therapy trial activity; IBiS research institute.
Spanish affiliate of MD Anderson; dedicated oncology trials site; Phase I–III; strong in solid tumors and hematologic malignancies.
IMIM research institute; strong in cardiovascular, neuroscience, oncology, and infectious disease trials; active Phase I program.
Spain's leading hematology center; nationally recognized for multiple myeloma, lymphoma, and hematopoietic cell transplantation trials.
IGTP research institute; strong in infectious disease (HIV), oncology, and immunology; major Phase II–IV site in the Barcelona metropolitan area.
Dedicated Phase I oncology centers within the Quirónsalud Group; early-phase first-in-human and first-in-class oncology trials across both campuses.
Spain's clinical research ecosystem is held together by a dense network of regulatory bodies, research institutes, industry associations, and CROs; many of which are among Europe's most influential.
National competent authority; authorized 930 trials in 2024; the most in the EU; introduced fast-track evaluation in 2024; Reference Member State in 28% of EU multinational studies.
Spain's main public health research agency; accredits the 35 Health Research Institutes (IIS) and coordinates the SCReN platform of clinical research units.
Oversees the National Health System (SNS) and the National Health Research Plan; drives clinical research policy and the network of accredited IIS institutes.
One of Europe's premier Phase I oncology centers; Molecular Prescreening Program; partner of NCI, EORTC, and major global sponsors; leader in breast, GI, and lung cancer trials.
Spain's flagship cancer research institute; generates the translational science pipeline that feeds Spain's clinical oncology trial network.
Catalonia's life sciences cluster organization; 5,368 active trials; 5th in Europe for scientific publications; coordinates the Barcelona clinical trial ecosystem.
Spain's pharmaceutical industry association; leads the BEST Project (public-private clinical research network); drives Spain's national clinical trials strategy.
Spain-based full-service CRO; oncology, CNS, cardiovascular, and metabolic specialist; manages end-to-end trials for international sponsors across Spanish sites.
Global CRO with strong Spanish operations; Prime Site network includes Vall d'Hebron; data management, monitoring, and regulatory affairs services.
Global CRO with Spanish offices; active in oncology, CNS, and rare disease trials; regulatory submission expertise for EU CTIS.
Spain is Europe's undisputed leader in clinical trial starts; 930 authorized in 2024, more than any other EU country; and the continent's most important oncology research hub outside Paris. Built on early regulatory harmonization, world-class hospitals, 47 million diverse patients, and a pharmaceutical industry that invested €849 million in clinical trials in a single decade, Spain isn't just competitive in Europe. It's competitive globally, ranking third in the world for clinical trial volume and second only to the US in participation in new drug studies. For sponsors building a European or global trial, Spain is not optional; it's foundational.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.